Resistance to BRAF Inhibition in Melanomas

被引：188
|
作者：
Solit, David B. [1 ]
Rosen, Neal [1 ,2 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Mol Pharmacol & Chem, New York, NY 10021 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2011年 / 364卷 / 08期
关键词：
RAF; PATHWAY; CRAF;
D O I：
10.1056/NEJMcibr1013704
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：772 / 774
页数：3
相关论文
共 50 条
  • [1] Cyclic cell state transition is associated with the adaptive resistance to BRAF inhibition in melanomas
    Su, Yapeng
    Lu, Xiang
    Li, Guideng
    Robert, Lidia
    Ng, Alphonsus
    Xue, Min
    Ribas, Antoni
    Baltimore, David
    Levine, Raphael
    Wei, Wei
    Heath, James
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [2] Mutant BRAF Melanomas-Dependence and Resistance
    Poulikakos, Poulikos I.
    Rosen, Neal
    [J]. CANCER CELL, 2011, 19 (01) : 11 - 15
  • [3] Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition
    Hardeman, Keisha N.
    Peng, Chengwei
    Paudel, Bishal B.
    Meyer, Christian T.
    Thong Luong
    Tyson, Darren R.
    Young, Jamey D.
    Quaranta, Vito
    Fessel, Joshua P.
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [4] Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition
    Keisha N. Hardeman
    Chengwei Peng
    Bishal B. Paudel
    Christian T. Meyer
    Thong Luong
    Darren R. Tyson
    Jamey D. Young
    Vito Quaranta
    Joshua P. Fessel
    [J]. Scientific Reports, 7
  • [5] Acquired Resistance to BRAF Inhibition Can Confer Cross-Resistance to Combined BRAF/MEK Inhibition
    Gowrishankar, Kavitha
    Snoyman, Stephanie
    Pupo, Gulietta M.
    Becker, Therese M.
    Kefford, Richard F.
    Rizos, Helen
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2012, 132 (07) : 1850 - 1859
  • [6] SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas
    Eliot Y. Zhu
    Jesse D. Riordan
    Marion Vanneste
    Michael D. Henry
    Christopher S. Stipp
    Adam J. Dupuy
    [J]. npj Precision Oncology, 6
  • [7] SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas
    Zhu, Eliot Y.
    Riordan, Jesse D.
    Vanneste, Marion
    Henry, Michael D.
    Stipp, Christopher S.
    Dupuy, Adam J.
    [J]. NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [8] Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas
    Roller, Devin G.
    Capaldo, Brian
    Bekiranov, Stefan
    Mackey, Aaron J.
    Conaway, Mark R.
    Petricoin, Emanuel F.
    Gioeli, Daniel
    Weber, Michael J.
    [J]. ONCOTARGET, 2016, 7 (03) : 2734 - 2753
  • [9] Pharmacologic inhibition of EphA2 in NRAS and BRAF mutant melanomas.
    Miao, Benchun
    Zhang, Jianming
    Ji, Zhenyu
    Njauw, Ching Ni
    Taylor, Michael
    Kumar, Raj
    Gray, Nathanael
    Tsao, Hensin
    [J]. CANCER RESEARCH, 2013, 73 (08)
  • [10] Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
    Spagnolo, Francesco
    Ghiorzo, Paola
    Queirolo, Paola
    [J]. ONCOTARGET, 2014, 5 (21) : 10206 - 10221
12345